



REVIEW

**REVISED** **The translational roadmap of the gut models, focusing on gut-on-chip [version 2; peer review: 2 approved]**Giulia Malaguarnera , Miriam Graute, Antoni Homs Corbera 

R&amp;D department, Cherry Biotech SAS, Rennes, Brittany, 35000, France

**v2** **First published:** 04 Jun 2021, 1:62  
<https://doi.org/10.12688/openreseurope.13709.1>  
**Latest published:** 18 Jan 2023, 1:62  
<https://doi.org/10.12688/openreseurope.13709.2>**Abstract**

It is difficult to model *in vitro* the intestine when seeking to include crosstalk with the gut microbiota, immune and neuroendocrine systems. Here we present a roadmap of the current models to facilitate the choice in preclinical and translational research with a focus on gut-on-chip. These micro physiological systems (MPS) are microfluidic devices that recapitulate *in vitro* the physiology of the intestine. We reviewed the gut-on-chips that had been developed in academia and industries as single chip and that have three main purpose: replicate the intestinal physiology, the intestinal pathological features, and for pharmacological tests.

**Keywords**

Gut-on-a-chip, Intestine-on-a-chip, Microbiota-on-a-chip, Colon-on-a-chip, Organ-on-a-chip, microfluidic, intestinal models

This article is included in the [Health Sciences gateway](#).This article is included in the [Horizon 2020 gateway](#).This article is included in the [Marie-Sklodowska-Curie Actions \(MSCA\) gateway](#).**Open Peer Review****Approval Status**  

	1	2
<b>version 2</b> (revision) 18 Jan 2023		 <a href="#">view</a>
<b>version 1</b> 04 Jun 2021	 <a href="#">view</a>	  <a href="#">view</a>

- Rosalba Parenti**, University of Catania, Catania, Italy  
**Nunzio Vicario**, University of Catania, Catania, Italy
- J. J. Hickman**, University of Central Florida, Orlando, USA  
**Mridu Malik**, Hesperos Inc, Orlando, USA

Any reports and responses or comments on the article can be found at the end of the article.



This article is included in the [Healthcare and Policy](#) collection.

**Corresponding author:** Giulia Malaguarnera ([giulia.malaguarnera@live.it](mailto:giulia.malaguarnera@live.it))

**Author roles:** **Malaguarnera G:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Graute M:** Data Curation, Formal Analysis, Investigation, Validation, Visualization, Writing – Original Draft Preparation; **Homs Corbera A:** Resources, Supervision, Visualization, Writing – Review & Editing

**Competing interests:** All authors are employed in the research and development department at Cherry Biotech (Rennes, France).

**Grant information:** This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No [845036], (Human gut microbiota on gut-on-a-chip [Goc-MM]) and grant agreement No [814168], (Research and Training in Early Life Nutrition to Prevent Disease [GROWTH]).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2023 Malaguarnera G *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Malaguarnera G, Graute M and Homs Corbera A. **The translational roadmap of the gut models, focusing on gut-on-chip [version 2; peer review: 2 approved]** Open Research Europe 2023, 1:62 <https://doi.org/10.12688/openreseurope.13709.2>

**First published:** 04 Jun 2021, 1:62 <https://doi.org/10.12688/openreseurope.13709.1>

**REVISED Amendments from Version 1**

The new version of the article has taken into account the suggestions from the peer reviewers, clarifying and correcting the inconsistency across the first version of the manuscript. More citations and consideration had been added for better contextualise the paper to the current literature.

**Any further responses from the reviewers can be found at the end of the article**

**Introduction**

The human gastrointestinal (GI) tract primarily processes food and absorbs nutrients, water, and minerals, while also playing key roles in immunity and in different neuroendocrine processes<sup>1</sup>. The physiological environments of different GI lumen sections are distinguished by their pH, redox potential, and transit time and they are deeply influenced by individual condition, diet, circadian clock, and physical activity<sup>2</sup>. A healthy gut is marked by effective digestion and absorption of food, normal and stable intestinal microbiota, effective immune status, and general wellbeing<sup>3</sup>. Poor quality diet, frequent use of antibiotics compromising gut microbiota biodiversity, aging<sup>4</sup> and epigenetic factors have been associated with digestive diseases and linked to non-communicable diseases (NCDs)<sup>5,6</sup>. Dietary risk factors contribute to 11 million deaths and 255 million cases of morbidity worldwide, according to analysis of the Global Burden of Diseases (GBD) Study 2017<sup>7</sup>. In a more recent GBD report<sup>8</sup>, the annualised rate of change between 2010 and 2019 for the Dietary risk factors assessed a decrease of -0.28, but an increase for the Metabolic risks factors (+1.46%), which can be also associated with the GI diseases<sup>9,10</sup>.

Considering the important role played by the gut in human physiology and pathology, considerable efforts have been invested to create relevant *in vitro* models for translational research and personalized medicine. Gut-on-chip (GOC) models provide an advanced and unique approach to combine and preserve the original biological components, the biophysical architecture, and the biophysical phenomena of the gut *in vitro*. GOCs are organs-on-a-chip (OOC), small *in vitro* devices based on microfluidic technology that aim to replicate the minimal functional units of the intestine, enabling to culture intestinal cells and bioptic tissues<sup>11</sup>. The GOCs have demonstrated so far capability to replicate: (1) specific physiopathological conditions (e.g. inflammation<sup>12</sup>, intestinal bowel diseases – IBD<sup>13</sup>, colon cancer<sup>14</sup>); (2) *in vitro* drug pharmaco-kinetics (e.g. bioavailability assays<sup>15</sup>, drug-to-drug interaction<sup>16</sup>); (3) host-microbes interactions (HMI)<sup>17-19</sup>.


**Translational potentials and challenges of current gut models**

The success rate of drug discovery and development from the preclinical phase to the clinical phases is only about 32%<sup>20</sup>. The same drugs are not necessarily going onto the clinical phase and succeeding. One of the main reasons of the high percentage of failures is due to the difficulty in finding preclinical models,

both *in vitro* and *in vivo*, that resemble the human physiology, the pathological pathways, and the pharmacological response. Despite the disruptive therapeutic modalities such as gene therapy and immunotherapy, the development of more predictive *in vitro* model to study the treatment efficacy and toxicity is critical. In the preclinical research, the model roadmap to study the human GI tract pass by *in silico*, *in vitro*, and *in vivo* (Figure 1). *In silico* approach is based in computer modelling and aims at producing algorithms or numerical models able to predict the drug effects. They have different level of complexity and include computational fluid dynamics (CFD)<sup>21</sup>, ordinary differential equations (ODEs)<sup>22,23</sup>, aged-based modelling (ABM)<sup>24,25</sup>, and genome scale modelling (GSM)<sup>26</sup>. For the development of *in silico* models, it is critical the reliability of input data that are coming from databases, data banks, data mining, data analysis tools, publications, homology models, and other repositories<sup>27</sup>. Data-based modelling approaches are effective for many ADME (absorption, distribution, metabolism, elimination) properties in relationship with the QSAR (quantitative structure-activity relationship). For example, computational models are used for molecular modelling with enzymes and their docking, drugs solubility and permeability in intestine and brain, prediction of hepatic metabolism and mechanistic models of tissue distribution<sup>28,29</sup>. The data acquired *in silico* requires validation to bridge the current gap between theoretical and experimental approaches<sup>30</sup>. In preclinical studies, a range of animal models are used, from small animals (mice and rats) to large animals (pigs, dogs, and non-human primates). This is done to study the effects of a potential treatment in a more complex system than the *in vitro* systems allow, considering the whole organism. Animal studies require ethical approval and their predictability is challenged by different diets and thus different gut microbiota composition from humans, different genomes, difficulties in handling and maintenance (particularly for large animals), and high costs<sup>30</sup>. The use of animal models is not limited to pharmacological studies as the gut-brain axis research is becoming of critical importance in understanding physiological mechanisms<sup>31,32</sup> and mental health disorders<sup>33</sup>.

*In vitro* models can be distinguished in static and dynamic models; the first are commonly culture epithelial cell lines on Transwell® insert<sup>15</sup>. The most used cell lines are the immortalized human-derived Caco-2, HT29 or HT29-MTX, or the animal-derived IPEC-J2. The advantages of culturing Caco-2 cells in Transwell®, under static condition, are that: it is the regulatory standard model for drug bioavailability assays<sup>34</sup>, it requires no ethical permissions as cells are commercially available, and it mimics features of both small and large intestine, despite being cells derived by colon cancer. However, there are some limitations to this static Caco-2 *in vitro* model. For instance, the human intestinal epithelium contains more than one cell type (enterocytes) and it is hard to accurately predict the human response to pathogens and drugs. In fact, the standard bioavailability assay usually does not consider factors like nutrients, microbiota, hormonal factors, plasma carrier proteins, peristalsis speed, or bile acids<sup>35</sup>. Moreover, scientists suggest to consider also the presence of mucus in the bioavailability and in the *in vitro* digestion, which can be possible by co-culturing

## Translational Roadmap of Preclinical Gut Models



**Figure 1. Roadmap of the translation in preclinical studies of gastrointestinal (GI) model in physiology, pharmacology, disease modelling and personalized medicine.** ADMET=Absorption, Distribution, Metabolism, Elimination, and Toxicology.

Caco-2 and HT29-MTX mucus-producing cells<sup>36,37</sup>. Recent studies have been working on including bacterial species, representing the gut microbiota, into an *in vitro* Caco-2/HT29 co-culture. The limitation to this is the restricted nutrient supply, and the time the mammalian and bacterial cells can co-exist in a static environment with build-up of bacterial metabolites and excessive growth rate of bacteria<sup>17,38</sup>. To overcome these limits, Caco-2 cells have been incorporated into macromodels and GOCs in the dynamic models, which use the fluids flows across the cell cultures.

Macromodels are bioreactors consisting of a series of compartments with different pressures, pH, flow rates, temperatures, and cells aiming to simulate the different GI sections by replicating their biochemical and biophysical parameters<sup>39,40</sup>. In these models, it is possible to evaluate the bioavailability of drugs and food, and their fermentation by using patient-derived microbiota<sup>41</sup>. However, macromodels require costly lab equipment and space, need stabilization of the microbiota before use, and some of these systems do not mimic peristalsis and lack dialysis for removing microbial acid products<sup>30</sup>.

On the other hand, when Caco-2 are cultivated in alternative GOCs, they express the morphological and functional

characteristic of the static *in vitro* Caco-2 monolayer, both in dynamic fluidic systems with transwells and simpler GOCs<sup>42</sup>. These models have the advantage to control intestinal histogenesis, physiology, mucus production, drugs, and nutrients response. This is possible by modulating several parameters: directional flow rates, mechanical deformation, fluid shear stress, and asymmetric stimulation of the apical and basolateral sides of developing epithelium. Delon *et al.* used a Hele-Shaw cell to investigate the main features of Caco-2 cells in a microfluidic device by applying several fluid shear stresses<sup>43</sup>. They demonstrated that Caco-2 reach confluency within 5 days (earlier than in the static *in vitro* models) and that shear stress contributes to morphology, phenotype, and function of the epithelial layer. This turned into better mimicking tight junction expression, mitochondrial activity, mucus production, microvilli density, vacuolization, and cytochrome P450 (CYP450) expression. Gene expression study of Caco-2 on GOCs revealed that expression of MUC17, a transmembrane mucin, was highly enhanced in the 3D villi model compared to a static monolayer culture<sup>43</sup>. In a more recent study, the altered gene expression profile of Caco-2 was compared in static condition versus the flow culturing condition in a GOCs after 21 days. Differences had been spotted in the cellular homeostasis, signal transduction, cell life cycle, and in the immunological responses<sup>44</sup>.

Besides the translational advancement of these GOCs models, there is still a lack of standardization among labs and intrinsic difficulties to scale-up their production. Moreover, like the other aforementioned *in vitro* models, the currently proposed GOCs are more physiologically relevant model with a reduced number of cell lines, and they generally do not comprise neuroendocrine or immune parameters. Interestingly, some GOCs incorporate organoids, enteroids, and biopsies<sup>11,45,46</sup>.

Another commonly used *in vitro* model of the gut consist of 3D organoids or enteroids, which can be grown from adult intestinal stem cells (ISCs), induced pluripotent stem cells (iPSCs) and primary intestinal epithelial cells (IEC). An advantage of these models is the reproduction of complex structures, including both epithelia and mesenchyme<sup>47</sup>. However, 3D-organoids have lower success in modelling diseases such as IBD because of difficulties maintaining the quality and quantity of cells due to high occurrence of inflammation and pre-apoptosis<sup>48</sup>. Challenges include viability (up to 48h), cost, and difficulties in accessing the lumen of the spheric structure for the application of microbiota and drugs. In pharmacology, there is potential to culture 2D organoids/enteroids in a monolayer to study drug interactions. Also in this case, when biopsies, enteroids or organoids have been integrated in GOCs it was possible to find some advantages in terms of better reproducibility of intestinal cytoarchitecture from a single donor<sup>11,49-51</sup>, more reliability in the results for personalized therapy, or longer time in culture in the case of the biopsies<sup>46,52,53</sup>.

### Focusing on GOCs: from academia to industries and their proof-of-concept

GOCs are microfluidic devices hosting cell or tissue cultures in a single chip. In [Table 1](#), we list each chip, its main features, and the level of industry involvement. GOCs may be used for bioavailability assays, intestinal absorption of nutrients<sup>12</sup> and drugs, and real time evaluation of uptake and transports of drugs. The US Food and Drug Administration (FDA), the European Medicine Agency (EMA), and the World Health Organization (WHO) recommend Caco-2 intestinal permeability assays as the standard model to determine the intestinal permeability rate and ratio of active pharmaceutical ingredients (API). These studies permit to compare the drug permeability from the apical to the basolateral side by considering the involvement of efflux transporter and active uptake transporters ([EMA Guideline on the investigation of drug interaction](#)). Multiple transporters of the adenosine triphosphate (ATP) binding cassette (ABC) active transporter family such as P-glycoprotein (P-gp) or multidrug resistance protein- (MDRP1 or ABCB1) and multidrug resistance protein-2 (MRP-2 or ABCC2) efflux pumps are expressed by Caco-2<sup>54</sup>. A pharmaceutical compound needs to exhibit an apparent permeability (Papp) coefficient of > 90% compared with metoprolol, the gold standard for positive control in Caco-2 cells to be considered for exemption from bioequivalence studies; according to the Biopharmaceutical Classification System (BCS)<sup>55</sup>. A systematic approach for the comparison of the BCS in static and in dynamic conditions on a GOC was done by Kulthong *et al.*<sup>15</sup>, but no significant improvements were found in drug bioavailability, probably due to the

very low shear stress applied in the GOC. In fact, in another GOC model based on 12-wells transwell insert connected to a bioreactor (Quasi-Vivo Kirkstall Ltd), applied fluid mechanical forces enhanced the absorbance of the fluorescein in a time-dependent manner<sup>56</sup>. Comparing a thiol-ene GOC with static *in vitro* culture<sup>42</sup>, the permeabilities of mannitol, insulin, and fluorescein isothiocyanate were not significantly higher. However, the Caco-2 grew and differentiated faster in the thiol-ene GOC, expressing P-glycoprotein 1 (P-gp), aminopeptidase activity and mucous proteins, which play important roles in the oral bioavailability. A GOC with integrated optical fibers developed by Kimura enabled to observe the transport of rhodamine 123 in real time<sup>57</sup>. Two organoid-derived intestine-on-chip used the Emulate commercially available chip, also containing a polydimethylsiloxane (PDMS) membrane, for a small intestine-on-chip<sup>16</sup> and colon-on-chip<sup>11</sup> models. The advantage of using organoids derived from healthy donors compared to the Caco-2 model is that they better reproduce the intestinal cytoarchitecture, cell-cell interactions, transporters, and the expression of the CYP3A4. This is particularly relevant in studies on pharmacokinetics and pharmacodynamics. Duodenal epithelial cells are cultivated on top of the membrane, while human intestinal microvascular endothelial cells (HIMECs) grown at the bottom. Sontheimer-Phelps *et al.* have isolated human donor crypts, growing organoids, dissociating the spheres, and seeding the cell mixture onto the chip<sup>11</sup>. This method replicated the mucus bilayer of the colon to a full diameter of 0.6mm. Unfortunately, they did not report how this affected the fluid velocity of the apical channel (height: 1.0 mm), nor did they take this into consideration when reporting the effect of shear on villi bending.

Several GOCs aim to target a specific disease, as in the case of the tumor-on-a-chip for nanoparticles developed by Carvalho and colleagues<sup>14</sup>. Shear stress on HCT-116 cells (a human colon cancer cell line) and human colonic microvascular endothelial cells (HCoMECs) recreated the angiogenesis sprouting typical of colon cancer. To replicate the intestinal tubules, Beaurivage C *et al.* integrated extracellular matrix (ECM)-supported intestinal tubules grown from Caco-2 cells into their perfused microfluidic devices, OrganoPlate®<sup>13</sup>. In this device, the cells exhibit cellular polarization, tight junction formation, and express key receptors. This GOC is easy to handle and allows different experimental settings for physiological, pathological, and pharmacological studies. However, limitations of this model are 1) the use of a rocker that, by switching inclination of +/- 7 degree every 8 minutes, results in non-uniform bidirectional shear stress; 2) the Caco-2 tubular structure of the chip remain stable only for 6 - 8h of perfusion<sup>58</sup>.

Dawson and colleagues developed their dual-flow biopsy-holding chamber as an improved Ussing chamber<sup>46</sup>. Biopsy culture was maintained for 68h at which point 80% of the tissue was alive as shown with lactate dehydrogenase (LDH) activity upon cell lysis. The longest culture time of intestinal explant tissue in a microfluidic device was reported by Baydoun and colleagues<sup>52</sup>. In their study on a PDMS GOC, they demonstrated 3 of 9 biopsies to be intact upon histological observation after 8 days. Yissachar and colleagues implemented a gut organ



**Table 1. List of main of gut-on-chip (GOC)s models and their characteristics, including those developed in academia, in industries or in collaboration.** AOI=Anoxic-oxic interface; COC=Cyclic Olefin Copolymer; GOC=gut-on-chip; HMI=Host Microbes Interaction; IBD=Intestinal Bowel Disease; IOC=Intestine-on-chip; PC=Polycarbonate; PDMS=Polydimethylsiloxane; PE=Polyester; PET=Polyethylene terephthalate; PMI-CHIP=physiodynamic mucosal interface-on-a-chip; PS=Polystyrene. Caco-2, CCD-18Co, CRC, and HCT-116 are colon cancer cell lines; HCoMEC=Human Colonic Microvascular Endothelial Cells; HIMECs=Human Intestinal Microvascular Endothelial Cells; HUVEC=Human umbilical vein endothelial cells; iPSC=Induced pluripotent stem cells; PBMC=Peripheral blood mononuclear cell; U937=human lung lymphoblast.

MODEL OF GOC	APPLICATION	CELLS/TISSUES	MEMBRANE (Y/N)	BULK MATERIALS	FLOW RATE (µL/MIN)	ACADEMIA (Y/N)	INDUSTRY (Y/N)
<b>HUMIX</b> <sup>18,59</sup>	<ul style="list-style-type: none"> <li>- HMI</li> <li>- Disease modelling (colorectal cancer)</li> <li>- Pharmacology (pre- and probiotics)</li> </ul>	Caco-2 + CCD-18Co; primary CRC cells (T6)	Yes PC 1 µm pores	PC and silicone gaskets	25	Yes	No
<b>GOC</b> <sup>17,48</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- HMI</li> </ul>	Caco-2 + HIMECs	Yes PDMS	PDMS	0.5	Yes	Modified from Emulate
<b>AOI</b> <sup>19</sup>	<ul style="list-style-type: none"> <li>- HMI</li> </ul>	Caco-2 + HIMECs	Yes PDMS	PDMS	0.833-3.333	Yes	Modified from Emulate
<b>IOC</b> <sup>11,16</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- HMI</li> <li>- Drug-to-drug interaction</li> </ul>	Primary; human derived organoids + HIMECs	Yes PDMS	PDMS	1	Yes	Yes Emulate
<b>PMI-CHIP</b> <sup>60</sup>	<ul style="list-style-type: none"> <li>- HMI</li> <li>- Disease modelling (IBD)</li> </ul>	Caco-2 or patients' organoids	Yes PDMS	PDMS	0.833-1667	Yes	No
<b>INTESTINAL MICROFLUIDIC MODEL</b> <sup>57</sup>	<ul style="list-style-type: none"> <li>- Pharmaceutical testing</li> </ul>	Caco-2	Yes PE	PDMS and PE	N/A	Yes	No
<b>TUMOR-ON-A-CHIP</b> <sup>14</sup>	<ul style="list-style-type: none"> <li>- Disease modelling (Colorectal Cancer)</li> <li>- Pharmaceutical testing</li> </ul>	HCT-116 + HCoMECs	No	PDMS	0.133	Yes	No
<b>GOFLOWCHIP</b> <sup>45</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> </ul>	iPSC derived organoids	No	matrigel, clear cast acrylic plastic, silicone gasket, borosilicate glass	0.083	Yes	Yes
<b>ORGANOTYPIC-ON-A-CHIP</b> <sup>53</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- HMI</li> </ul>	Biopsy (mouse intestinal section)	No	PDMS, collagen gel matrix	16.67	Yes	No
<b>DUAL FLOW BIOREACTOR</b> <sup>56</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- Pharmaceutical testing</li> </ul>	Caco-2	Yes PC	PDMS	100-400	Yes	Yes Kirkstall
<b>USSING CHAMBER ON A CHIP</b> <sup>16</sup>	<ul style="list-style-type: none"> <li>- Disease modelling (IBD)</li> </ul>	Human Intestinal Biopsy	Yes PDMS	Glass, petroleum jelly	4	Yes	No

MODEL OF GOC	APPLICATION	CELLS/TISSUES	MEMBRANE (Y/N)	BULK MATERIALS	FLOW RATE (µL/MIN)	ACADEMIA (Y/N)	INDUSTRY (Y/N)
<b>MOTIF</b> <sup>61</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- HIMT</li> </ul>	Caco-2, HUVECs, PBMCs, primary macrophages	Yes PET	COC	25-50	Yes	Yes ChipShop GmbH
<b>THIOL-ENE BASED MICROFLUIDIC CHIP FOR INTESTINAL TRANSPORT STUDIES</b> <sup>42</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- Pharmaceutical testing</li> </ul>	Caco-2	Yes Thiol-ene coated Teflon	PMMA, PDMS, tetra-thiol moieties	0.5-3	Yes	No
<b>GOC</b> <sup>15</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- Pharmaceutical testing</li> </ul>	Caco-2	Yes PET	Glass, PET	0.4167	Yes	Yes Micronit
<b>NUTRICHIP</b> <sup>12</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- Disease modelling (inflammation)</li> </ul>	Caco-2 + U937	Yes PET	PMMA, PS, PDMS	0.6-2	Yes	No
<b>ORGANOPLATE</b> <sup>3,58</sup>	<ul style="list-style-type: none"> <li>- Physiological characterization</li> <li>- Disease modelling (IBD)</li> <li>- Pharmaceutical testing</li> </ul>	Caco-2	No	PS, glass, proprietary polymers	N/A	No	Yes Mimetas

culture, accommodating a mice gut tissue fragment in a bath of nutrients<sup>53</sup>. The researchers cocultured *ex vivo* intestinal tissue with intestinal microbiota and investigated crosstalk with the immune system and expression of neuronal-specific genes. Limits of this model include the short length of experiments (structure degradation after 30–40 hours) and the microbiota overgrowth (24 hours). Scientists from Paul Wilmes group have developed and patented HuMiX, the “Human Microbial Cross-talk” model<sup>59</sup>. This GOC co-cultures Caco-2 and bacteria, either *Lactobacillus rhamnosus GG* (LGG) or *Bacteroides caccae*<sup>18</sup>. HuMiX is made from polycarbonate (PC) and therefore has the potential of large-scale production. However, the Caco-2 and the microbiota are separated by a PC membrane which may be a limitation, because only indirect interactions can be assessed. Furthermore, the rigid membrane does not allow the chip to simulate peristalsis. On the contrary, the peristalsis is part of the GOC described by Jalili-Firoozinezhad and colleagues<sup>17,62</sup>. This GOC is a Polydimethylsiloxane (PDMS) microfluidic two-channel device containing a porous membrane coated with ECM. The Caco-2 cells are cultured on top of the membrane, while below the human intestinal microvascular endothelial cells (HIMECs) lies. The peristaltic movement is controlled by two lateral vacuum chambers that stretch the membrane and regulate the suction force<sup>48</sup>, like in the Emulate chips. The gut microbiota in the chip lived for up to 5 days, more than doubling the 48h of static Caco-2 monoculture. A modified chip, called anoxic-oxic interface-on-a-chip (AOI Chip)<sup>19</sup>, was made by co-cultivating the Caco-2 cells with two obligate anaerobic bacteria, *Bifidobacterium adolescentis* and *Eubacterium hallii*. The authors demonstrated that AOI does not compromise the viability, mucin production, barrier function, and the expression of proteins in the intestinal epithelial layer. Moreover, to produce the anoxic environment in the chip while oxic culture media was flowed in the oxic chamber, it was sufficient to precondition culture media in an anoxic chamber. The same research group have more recently developed their own GOC called 3D physiodynamic mucosal interface-on-a-chip (PMI Chip)<sup>60</sup>. The novelty introduced with the PMI Chip is the multiaxial stretching motion that provides the tortuosity of hydrodynamic flow with approximately 5% in cell strain at 0.15 Hz frequency. MOTiF biochips, designed by microfluidic ChipShop GmbH, is a microfluidic chip in polystyrol (PS) initially used to seed endothelial cells, human umbilical vein endothelial cells (HUVEC)<sup>61</sup>. A limitation of the study is the oxygen gradient, which is difficult to measure or control, because bacteria and fungi are sensitive to the gas composition, temperature, and humidity<sup>63</sup>. Following the differentiation of Caco-2 cells (which was faster compared to the transwell model), the authors demonstrated the possibility of colonization with bacteria (*L. rhamnosus*) and the fungal pathogen *Candida albicans* showing the competitive mechanism *in vitro*.

### Bulk and membrane materials

Materials employed in fabrication represent a crucial step and choosing a right material based on the application of the chip is not straightforward<sup>64</sup>. One of the main bottlenecks to scale up the GOC are the materials used to manufacture them<sup>65</sup>. PDMS is easy to prototype, elastic and optically transparent, but the costs are higher for mass production, it absorbs low molecular

weight hydrophobic molecules, such as drug compounds, it is permeable to carbon dioxide (CO<sub>2</sub>) and it has rather unstable surface properties<sup>66</sup>. However, limited gas permeability of PDMS has been turned into an advantage in HMI studies, controlling for oxygen and anoxic flows to grow different species of gut bacteria<sup>19</sup>. Thermoplastic materials, such as polycarbonate (PC), Poly(methyl methacrylate) PMMA, or Cycloolefins such as cyclic olefin polymers (COP) and copolymers (COC) are easier to produce in larger scale, through injection molding strategies<sup>67</sup>. However, they need to be accurately selected to facilitate sterilization and the needed optical properties for a given assay. PC is easier to produce in larger scale, through injection molding strategies, and can be sterilized in autoclave, but it is more rigid, limiting its use to induce peristaltic deformations, and it has a poor resistance to organic solvents as well as some autofluorescence and sensitivity to ultraviolet (UV) radiation which could be minor inconveniences. COP and COC show low molecules absorption, minimum autofluorescence and excellent optical properties. However, thermoplastics are generally rigid materials and a flexible membrane, or a suitable biological structure should also be provided to induce realistic peristaltic deformations when needed in some GOC models<sup>68</sup>. In most of the GOCs reviewed, membranes serve as support for cell culture (Caco-2 or primary cells) and to simulate peristalsis in combination with flow. They vary not only in manufacturing process and material, but also with regards to pore size, cell-to-cell distance, and overall porosity. Membrane permeability, a function of porosity, pore sizes and specific material properties like charge, is highly relevant for pharmacodynamic testing, such as bioavailability tests conducted in GOCs and other *in vitro* models. All of these GOCs have been trialed with synthetic membranes such as nylon, PDMS, PC, or polyester such as polyethylene terephthalate (PET). Some, for example Esch *et al.*<sup>69</sup> and Kim *et al.*<sup>62</sup> precondition or coat these membranes with collagen 1 to promote cell adhesion. Several papers lacked detail on the exact characteristics of the materials, simply stating that PC or PE from commercial transwells were used.

PC is one of the more commonly used synthetic membrane material due to low cost and rigid nature, as well as its resistance to autoclave pressure and temperature. Aspects such as thickness and porosity can be precisely controlled. However, it is not naturally biocompatible, leading some researchers to precondition the surface with collagen or mucin<sup>18,70</sup>. Other popular membrane materials are polyesters, including PET. Along with PC, they are widely established in transwell inserts and do not optically interfere in a critical way with microscopy.

Other bioengineering approaches for mimicking the villi structure had been explored and included in larger scaffolds (like the macromodels above described), but not in the GOC models. Other membranes that may be tested in GOC are a combination of synthetic and natural components<sup>71–73</sup>. Examples include 3D bioprinted membranes made of Poly(ethylene glycol) dimethacrylate (PEGDMA); gelatin methacrylate (GelMA); Lutrol; gelatin also mixed with chitosan; combination of fibrinogen, alginate, gelatin, and polyacrylamide; collagen; or silk proteins with spiral pattern<sup>30</sup>.



## Conclusions and future perspective of GOC

GOCs are microfluidic devices that respond to the need of GI models that consider the ethical dilemmas involved in direct studies on humans (Declaration of Helsinki<sup>74</sup>) and animal testing. In fact, The final aim of these devices is to refine, reduce, and ultimately replace animal testing based on the 3Rs<sup>75</sup> and utilise a closer model to the human physiology. Considering that the gut microbiota is also specie-specific and is influenced by nutrition<sup>76</sup>, animal models are often less reliable models for GI compared to other organs<sup>77</sup>. Efforts have been made to produce new GOCs or modify existing ones for new applications. There is however a lack of reported effort on stabilizing protocols to be applied on larger scales and ensuring the product is “fit for a purpose”<sup>78</sup>. In fact, modifications to the geometry design and the protocols seems to be the major concerns of researchers in this field, making OOCs a niche not ready for a larger market and even less ready for the development

and testing of therapeutic compounds. In the future, the GOCs described may have a higher output in *in vitro* studies on HMI, disease modelling, personalized medicine, and pharmacological studies. Fluid mechanical forces in GOCs enable to achieve intestinal physiological features more realistically when compared to other *in vitro* methods not incorporating biophysical stimulus<sup>79</sup>. Therefore, GOCs can reduce the time for drug development and translational approaches with fewer ethical concerns than animal testing. The GOC approach is very promising but translation into industrial and commercial products aimed to cover the drug industry and healthcare markets require a larger effort to achieve robustness, to guarantee repeatability and to prove reliability.

## Data availability

No data are associated with this article.

## References

- Vanner SJ, Greenwood-Van Meerveld B, Mawe GM, *et al.*: **Fundamentals of neurogastroenterology: Basic science.** *Gastroenterology.* 2016; **150**(6): 1280–1291.  
[Publisher Full Text](#)
- Aoyama S, Shibata S: **Time-of-Day-Dependent Physiological Responses to Meal and Exercise.** *Front Nutr.* 2020; **7**: 18.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bischoff SC: **“Gut health”: A new objective in medicine?** *BMC Med.* 2011; **9**: 24.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ianiro G, Tilg H, Gasbarrini A: **Antibiotics as deep modulators of gut microbiota: Between good and evil.** *Gut.* 2016; **65**(11): 1906–1915.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Malaguarnera G, Leggio F, Vacante M, *et al.*: **Probiotics in the gastrointestinal diseases of the elderly.** *J Nutr Heal Aging.* 2012; **16**(4): 402–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- GBD 2017 Causes of Death Collaborators: **Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017.** *Lancet.* 2018; **392**(10159): 1736–1788.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- GBD 2017 Diet Collaborators: **Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.** *Lancet.* 2019; **393**(10184): 1958–1972.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- GBD 2019 Risk Factors Collaborators: **Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.** *Lancet.* 2020; **396**(10258): 1223–1249.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Watanabe S, Hojo M, Nagahara A: **Metabolic syndrome and gastrointestinal diseases.** *J Gastroenterol.* 2007; **42**(4): 267–274.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- De Filippis A, Ullah H, Baldi A, *et al.*: **Gastrointestinal disorders and metabolic syndrome: Dysbiosis as a key link and common bioactive dietary components useful for their treatment.** *Int J Mol Sci.* 2020; **21**(14): 4929.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sontheimer-phelps A, Chou DB, Tovaglieri A, *et al.*: **Colon *In Vivo* Inner & Outer Mucus Layer Colon Chip Mucus Layer Swelling Mucus Layer Colon Organoids.** *Cell Mol Gastroenterol Hepatol.* 2019.
- Ramadan Q, Jafarpoorchehab H, Huang C, *et al.*: **NutriChip: Nutrition analysis meets microfluidics.** *Lab Chip.* 2013; **13**(2): 196–203.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Beaurivage C, Naumovska E, Chang YX, *et al.*: **Development of a gut-on-a-chip model for high throughput disease modeling and drug discovery.** *Int J Mol Sci.* 2019; **20**(22): 5661.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Carvalho MR, Barata D, Teixeira LM, *et al.*: **Colorectal tumor-on-a-chip system: A 3D tool for precision onco-nanomedicine.** *Sci Adv.* 2019; **5**(5): eaaw1317.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kulthong K, Duivenvoorde L, Sun H, *et al.*: **Microfluidic chip for culturing intestinal epithelial cell layers: Characterization and comparison of drug transport between dynamic and static models.** *Toxicol In Vitro.* 2020; **65**: 104815.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kasendra M, Tovaglieri A, Sontheimer-Phelps A, *et al.*: **Development of a primary human Small Intestine-on-a-Chip using biopsy-derived organoids.** *Sci Rep.* 2018; **8**(1): 2871.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jalili-Firoozinezhad S, Gazzaniga FS, Calamari EL, *et al.*: **A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip.** *Nat Biomed Eng.* 2019; **3**(7): 520–531.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Shah P, Fritz JV, Glaab E, *et al.*: **A microfluidics-based *in vitro* model of the gastrointestinal human-microbe interface.** *Nat Commun.* 2016; **7**: 11535.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Shin W, Wu A, Massidda MW, *et al.*: **A robust longitudinal co-culture of obligate anaerobic gut microbiome with human intestinal epithelium in an anoxic-oxic interface-on-a-chip.** *Front Bioeng Biotechnol.* 2019; **7**: 13.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Takebe T, Imai R, Ono S: **The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development.** *Clin Transl Sci.* 2018; **11**(6): 597–606.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ferrua MJ, Singh RP: **Computational Modeling of Gastrointestinal Fluid Dynamics.** In: Cheng LK, Pullan AJ, Farrugia G, eds. *New Advances in Gastrointestinal Motility Research.* Dordrecht: Springer Netherlands; 2013; 243–266.  
[Publisher Full Text](#)
- Wilkinson MHF: **Model intestinal microflora in computer simulation: A simulation and modeling package for host-microflora interactions.** *IEEE Trans Biomed Eng.* 2002; **49**(10): 1077–1085.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Taghipoor M, Lescoat P, Licois JR, *et al.*: **Mathematical modeling of transport and degradation of feedstuffs in the small intestine.** *J Theor Biol.* 2012; **294**: 114–121.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hoertel N, Blachier M, Blanco C, *et al.*: **A stochastic agent-based model of the SARS-CoV-2 epidemic in France.** *Nat Med.* 2020; **26**(9): 1417–1421.  
[PubMed Abstract](#) | [Publisher Full Text](#)
- Shashkova T, Popenko A, Tyakht A, *et al.*: **Agent based modeling of human gut microbiome interactions and perturbations.** *PLoS One.* 2016; **11**(12): e0148386.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

26. Le Feunteun S, Mackie AR, Dupont D: **In silico trials of food digestion and absorption: how far are we?** *Curr Opin Food Sci.* 2020; **31**: 121–125. [Publisher Full Text](#)
27. Havenaar R, Bellmann S: **Results from a Validated in vitro Gastrointestinal Model (TIM) used as input Data for in silico Modeling Give Highly Predictive Information for the Human Situation.** *Med Rec Arch. [S.l.]*; 2022; **10**(9). Date accessed: 29 oct. 2022. [Publisher Full Text](#)
28. Yamashita F, Hashida M: **In silico approaches for predicting ADME properties of drugs.** *Drug Metab Pharmacokinet.* 2004; **19**(5): 327–38. [PubMed Abstract](#) | [Publisher Full Text](#)
29. Parenti R, Vicario N: **Peer Review Report For: The translational roadmap of the gut models, focusing on gut-on-chip [version 1; peer review: 1 approved, 1 approved with reservations].** *Open Res Europe.* 2021; **1**: 62. [Reference Source](#)
30. Fois CAM, Le TYL, Schindeler A, et al.: **Models of the Gut for Analyzing the Impact of Food and Drugs.** *Adv Healthc Mater.* 2019; **8**(21): e1900968. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Tan HE, Sisti AC, Jin H, et al.: **The gut-brain axis mediates sugar preference.** *Nature.* 2020; **580**(7804): 511–516. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Zimmerman CA, Huey EL, Ahn JS, et al.: **A gut-to-brain signal of fluid osmolarity controls thirst satiation.** *Nature.* 2019; **568**(7750): 98–102. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Nithianantharajah J, Balasuriya GK, Franks AE, et al.: **Using Animal Models to Study the Role of the Gut-Brain Axis in Autism.** *Curr Dev Disord Rep.* 2017; **4**(2): 28–36. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Hubatsch I, Ragnarsson EGE, Artursson P: **Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers.** *Nat Protoc.* 2007; **2**(9): 2111–2119. [PubMed Abstract](#) | [Publisher Full Text](#)
35. Costa J, Ahluwalia A: **Advances and Current Challenges in Intestinal in vitro Model Engineering: A Digest.** *Front Biotechnol.* 2019; **7**: 144. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
36. Mahler GJ, Shuler ML, Glahn RP: **Characterization of Caco-2 and HT29-MTX cocultures in an in vitro digestion/cell culture model used to predict iron bioavailability.** *J Nutr Biochem.* 2009; **20**(7): 494–502. [PubMed Abstract](#) | [Publisher Full Text](#)
37. Malik M, Yang Y, Fathi P, et al.: **Critical Considerations for the Design of Multi-Organ Microphysiological Systems (MPS).** *Front Cell Dev Biol.* 2021; **9**: 721338. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Hickman JJ, Malik M: **Peer Review Report For: The translational roadmap of the gut models, focusing on gut-on-chip [version 1; peer review: 1 approved, 1 approved with reservations].** *Open Res Europe.* 2021; **1**: 62. [Publisher Full Text](#)
39. de Wiele T, den Abbeele P, Ossieur W, et al.: **The Simulator of the Human Intestinal Microbial Ecosystem (SHIME®).** In: Verhoeckx K, Cotter P, López-Expósito I, et al., eds. *The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models.* Cham: Springer International Publishing; 2015; 305–317. [Publisher Full Text](#)
40. Wiese M, Khakimov B, Nielsen S, et al.: **CoMiniGut-A small volume in vitro colon model for the screening of gut microbial fermentation processes.** *PeerJ.* 2018; **6**(1): e4268. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Guzman-Rodriguez M, McDonald JAK, Hyde R, et al.: **Using bioreactors to study the effects of drugs on the human microbiota.** *Methods.* 2018; **149**: 31–41. [PubMed Abstract](#) | [Publisher Full Text](#)
42. Tan HY, Trier S, Rahbek UL, et al.: **A multi-chamber microfluidic intestinal barrier model using Caco-2 cells for drug transport studies.** *PLoS One.* 2018; **13**(5): e0197101. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Delon LC, Guo Z, Oszmiana A, et al.: **A systematic investigation of the effect of the fluid shear stress on Caco-2 cells towards the optimization of epithelial organ-on-chip models.** *Biomaterials.* 2019; **225**: 119521. [PubMed Abstract](#) | [Publisher Full Text](#)
44. Kulthong K, Hooiveld GJEJ, Duivenvoorde L, et al.: **Transcriptome comparisons of in vitro intestinal epithelia grown under static and microfluidic gut-on-chip conditions with in vivo human epithelia.** *Sci Rep.* 2021; **11**(1): 3234. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Sidar B, Jenkins BR, Huang S, et al.: **Long-term flow through human intestinal organoids with the gut organoid flow chip (GOFlowChip).** *Lab Chip.* 2019; **19**(20): 3552–3562. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Dawson A, Dyer C, Macfie J, et al.: **A microfluidic chip based model for the study of full thickness human intestinal tissue using dual flow.** *Biomicrofluidics.* 2016; **10**(6): 064101. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Yoo JH, Donowitz M: **Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases.** *World J Gastroenterol.* 2019; **25**(30): 4125–4147. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Kim HJ, Ingber DE: **Gut-on-a-Chip microenvironment induces human intestinal cells to undergo villus differentiation.** *Integr Biol (Camb).* 2013; **5**(9): 1130–40. [PubMed Abstract](#) | [Publisher Full Text](#)
49. Sontheimer-Phelps A, Chou DB, Tovaglieri A, et al.: **Human Colon-on-a-Chip Enables Continuous In Vitro Analysis of Colon Mucus Layer Accumulation and Physiology.** *Cell Mol Gastroenterol Hepatol.* 2020; **9**(3): 507–526. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Tovaglieri A, Sontheimer-Phelps A, Geirnaert A, et al.: **Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites.** *Microbiome.* 2019; **7**(1): 43. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Sances S, Ho R, Vatine G, et al.: **Human iPSC-Derived Endothelial Cells and Microengineered Organ-Chip Enhance Neuronal Development.** *Stem Cell Reports.* 2018; **10**(4): 1222–1236. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Baydoun M, Treizebré A, Follet J, et al.: **An interphase microfluidic culture system for the study of ex vivo intestinal tissue.** *Micromachines (Basel).* 2020; **11**(2): 150. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Yissachar N, Zhou Y, Ung L, et al.: **An Intestinal Organ Culture System Uncovers a Role for the Nervous System in Microbe-Immune Crosstalk.** *Cell.* 2017; **168**(6): 1135–1148.e12. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
54. Pham-The H, Garrigues T, Bermejo M, et al.: **Provisional classification and in silico study of biopharmaceutical system based on Caco-2 cell permeability and dose number.** *Mol Pharm.* 2013; **10**(6): 2445–2461. [PubMed Abstract](#) | [Publisher Full Text](#)
55. Dahan A, Miller JM, Amidon GL: **Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.** *AAPS J.* 2009; **11**(4): 740–746. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Giusti S, Sbrana T, La Marca M, et al.: **A novel dual-flow bioreactor simulates increased fluorescein permeability in epithelial tissue barriers.** *Biotechnol J.* 2014; **9**(9): 1175–1184. [PubMed Abstract](#) | [Publisher Full Text](#)
57. Kimura H, Yamamoto T, Sakai H, et al.: **An integrated microfluidic system for long-term perfusion culture and on-line monitoring of intestinal tissue models.** *Lab Chip.* 2008; **8**(5): 741–746. [PubMed Abstract](#) | [Publisher Full Text](#)
58. Trietsch SJ, Naumovska E, Kurek D, et al.: **Membrane-free culture and real-time barrier integrity assessment of perfused intestinal epithelium tubes.** *Nat Commun.* 2017; **8**(1): 262. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. Greenhalgh K, Ramiro-Garcia J, Heinken A, et al.: **Integrated In Vitro and In Silico Modeling Delineates the Molecular Effects of a Symbiotic Regimen on Colorectal-Cancer-Derived Cells.** *Cell Rep.* 2019; **27**(5): 1621–1632.e9. [PubMed Abstract](#) | [Publisher Full Text](#)
60. Shin YC, Shin W, Koh D, et al.: **Three-Dimensional Regeneration of Patient-Derived Intestinal Organoid Epithelium in a Physiodynamic Mucosal Interface-on-a-Chip.** *Micromachines (Basel).* 2020; **11**(7): 663. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Maurer M, Gresnigt MS, Last A, et al.: **A three-dimensional immunocompetent intestine-on-chip model as in vitro platform for functional and microbial interaction studies.** *Biomaterials.* 2019; **220**: 119396. [PubMed Abstract](#) | [Publisher Full Text](#)
62. Kim HJ, Huh D, Hamilton G, et al.: **Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow.** *Lab Chip.* 2012; **12**(12): 2165–2174. [PubMed Abstract](#) | [Publisher Full Text](#)
63. Andresen LC, Dungait JAJ, Bol R, et al.: **Bacteria and fungi respond differently to multifactorial climate change in a temperate heathland, traced with <sup>13</sup>C-glycine and FACE CO<sub>2</sub> inc.** *PLoS One.* 2014; **9**(1): e85070. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
64. Ren K, Zhou J, Wu H: **Materials for microfluidic chip fabrication.** *Acc Chem Res.* 2013; **46**(11): 2396–2406. [PubMed Abstract](#) | [Publisher Full Text](#)
65. Zhang B, Radisic M: **Organ-on-A-chip devices advance to market.** *Lab Chip.* 2017; **17**(14): 2395–2420. [PubMed Abstract](#) | [Publisher Full Text](#)
66. Whitesides GM: **The origins and the future of microfluidics.** *Nature.* 2006; **442**(7101): 368–373. [PubMed Abstract](#) | [Publisher Full Text](#)
67. Qin D, Xia Y, Whitesides GM: **Soft lithography for micro- and nanoscale patterning.** *Nat Protoc.* 2010; **5**(3): 491–502. [PubMed Abstract](#) | [Publisher Full Text](#)
68. Chae SK, Ryoo JH, Lee SH: **Thin and large free-standing PDMS membrane by using polystyrene Petri dish.** *Biochip J.* 2012; **6**(2): 184–190. [Publisher Full Text](#)
69. Esch MB, Sung JH, Yang J, et al.: **On chip porous polymer membranes for integration of gastrointestinal tract epithelium with microfluidic 'body-on-a-chip' devices.** *Biomed Microdevices.* 2012; **14**(5): 895–906. [PubMed Abstract](#) | [Publisher Full Text](#)

70. Chen HJ, Miller P, Shuler ML: **A pumpless body-on-a-chip model using a primary culture of human intestinal cells and a 3D culture of liver cells.** *Lab Chip.* 2018; **18**(14): 2036–2046.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
71. Bakarich SE, Panhuis MIH, Beirne S, *et al.*: **Extrusion printing of ionic-covalent entanglement hydrogels with high toughness.** *J Mater Chem B.* 2013; **1**(38): 4939–4946.  
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Hong S, Sycks D, Chan HF, *et al.*: **3D Printing of Highly Stretchable and Tough Hydrogels into Complex, Cellularized Structures.** *Adv Mater.* 2015; **27**(27): 4035–4040.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
73. Skardal A, Zhang J, McCoard L, *et al.*: **Photocrosslinkable hyaluronan-gelatin hydrogels for two-step bioprinting.** *Tissue Eng Part A.* 2010; **16**(8): 2675–2685.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. World Medical Association: **World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.** *JAMA.* 2013; **310**(20): 2191–2194.  
[PubMed Abstract](#) | [Publisher Full Text](#)
75. Herrmann K, Pistollato F, Stephens ML: **Beyond the 3Rs: Expanding the use of human-relevant replacement methods in biomedical research.** *ALTEX.* 2019; **36**(3): 343–352.  
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Gevers D, Knight R, Petrosino JF, *et al.*: **The Human Microbiome Project: A Community Resource for the Healthy Human Microbiome.** *PLoS Biol.* 2012; **10**(8): e1001377.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
77. Kennedy EA, King KY, Baldrige MT: **Mouse microbiota models: Comparing germ-free mice and antibiotics treatment as tools for modifying gut bacteria.** *Front Physiol.* 2018; **9**: 1534.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Taute F, Homs-Corbera A, Gaudriault P: **The challenges and considerations for emerging or future entrepreneurial researchers in microphysiological systems [version 1; peer review: 2 approved with reservations].** *Open Res Eur.* 2021; **1**: 38.  
[Publisher Full Text](#)
79. Polachek WJ, Li R, Uzel SGM, *et al.*: **Microfluidic platforms for mechanobiology.** *Lab Chip.* 2013; **13**(12): 2252–2267.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

# Open Peer Review

Current Peer Review Status:  

---

## Version 2

Reviewer Report 02 February 2023

<https://doi.org/10.21956/openreseurope.16706.r30667>

© 2023 Hickman J et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**J. J. Hickman**

Hybrid Systems Lab, NanoScience Technology Cente, University of Central Florida, Orlando, FL, USA

**Mridu Malik**

Hesperos Inc, Orlando, USA

The authors have addressed all previous concerns.

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** I have a background in working with both static and dynamic in vitro organ models. I have worked on a static Caco-2/HT29-MTX cell based gut model to analyze the effects of engineered nanoparticles and other food additives on gut permeability, nutrient transport, and tight junction distribution in presence of a bacterial mock community. My experience with dynamic in vitro systems entails developing and optimizing a two-organ microphysiological system for secondary drug toxicity study. My work has made me well versed with the complexities involved in building a physiologically relevant microphysiological system and the significant factors that need to be considered to design it.

**We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

## Version 1

Reviewer Report 26 January 2022

<https://doi.org/10.21956/openreseurope.14783.r28371>

© 2022 Hickman J et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



### J. J. Hickman

<sup>1</sup> Hybrid Systems Lab, NanoScience Technology Center, University of Central Florida, Orlando, FL, USA

<sup>2</sup> Hybrid Systems Lab, NanoScience Technology Center, University of Central Florida, Orlando, FL, USA

### Mridu Malik

<sup>1</sup> Hesperos Inc, Orlando, USA

<sup>2</sup> Hesperos Inc, Orlando, USA

The review article by Malaguarnera, Graute, and Corbera focuses on the current gut-on chip devices available in academia and the industrial sector, the challenges with using traditional static culture models, and the scale-up and design concerns with building the GOC models. The authors do a good job at pointing out the limitations to the different models included in the paper. The table listing the different GOC models available today is quite comprehensive, enabling the readers to have access to all the information in a single place. The article ends with a strong conclusion summarizing the current state of gut-on-chip research.

I would suggest minor revisions to the paper. The article points out the limitation of Caco-2 models by stating they lack mucus and microbiota but fails to provide all relevant information on the available co-culture models of Caco-2/HT29 models with microbiota components. I would suggest expanding on this aspect more, and then outlining the challenges with maintaining the Caco-2/HT29/microbiota tri-culture for longer durations and its limited physiological relevance compared to GOCs.

The placement of some information is erratic and lacks overall flow to the read. Changes have been suggested below to address these concerns.

#### **Introduction - Translational potentials and challenges of current gut models - Page 3:**

- Paragraph 1: The resource is for only academic drug discovery and development. 32% success rate is associated with only the pre-clinical phase. The same drugs are not necessarily going onto the clinical phase and succeeding.
- Paragraph 2: GOCs are also *in vitro*, the difference arises between the flow of fluid across the intestinal barrier, static vs dynamic. Please make it clear that this paragraph deals with the static system.
- Include information on co-culture of Caco-2 and HT29 cells, where HT29 cells are mucin secreting cells, forming a mucus layer on the Caco-2 monolayer. Yes, there are limitations to the static gut model, however, complete lack of mucus is not one of them.
- See. Mahler G. J, Characterization of Caco-2 and HT29-MTX cocultures in an *in vitro* digestion/cell culture model used to predict iron bioavailability. 2009

- Recent studies have been working on including bacterial species, representing the gut microbiota, into an *in vitro* Caco-2/HT29 co-culture. The limitation to this is the restricted nutrient supply, and the time the mammalian and bacterial cells can co-exist in a static environment with build-up of bacterial metabolites and excessive growth rate of bacteria. Please address the same by referencing research on the topic.

**Page 4:**

- Paragraph 1: I wouldn't say GOCs are a simplified representation. There are a lot of complexities with constructing an organ-on-chip model. The better suited term would be 'more physiologically relevant' model.
- Inconsistency with the use of GOC and GOCs.
- Paragraph 2: I would add a reference paper to support this statement, "However, 3D-organoids have lower success in modelling diseases such as IBD because of difficulties maintaining the quality and quantity of cells due to high occurrence of inflammation and pre-apoptosis."
- Paragraph 3: This paragraph should precede the introduction to different types of *in vitro* gut models in this section. The difference in data reproducibility when moving from animal trials to human trials is one of the primary reasons for the interest in the organ-on-chip model. So it is necessary to establish that before explaining the types of models.

**Page 7:**

- Right column, 10 lines from the bottom: "... more than doubling the 48h of static Caco-2 monoculture." - This is a contradiction to your claim in paragraph 2 of section 'Translational potentials and challenges of current gut models' that static 2D Caco-2 cultures lack microbiota.

**Page 8:**

- Left column, end of the initial paragraph: The statement- "... and the fungal pathogen candida albicans.." should be changed to "... and the fungal pathogen *Candida albicans* ...". *Candida albicans* should be in italics to correctly represent the scientific name of the organism.
- Left column, Bulk and Membrane paragraph: "PDMS is easy to prototype, elastic and optically transparent, but the costs are higher for mass production, it absorbs little hydrophobic molecules, such as drug compounds, it is permeable to carbon dioxide (CO<sub>2</sub>) and it has rather unstable surface properties<sup>57</sup>." - This statement seems to imply there is little absorption of hydrophobic molecules and that was not the authors intent. To be more clear I think this should be worded "it absorbs low molecular weight hydrophobic molecules"

**References**

1. Mahler GJ, Shuler ML, Glahn RP: Characterization of Caco-2 and HT29-MTX cocultures in an *in vitro* digestion/cell culture model used to predict iron bioavailability. *J Nutr Biochem*. 2009; **20** (7): 494-502 [PubMed Abstract](#) | [Publisher Full Text](#)



**Is the topic of the review discussed comprehensively in the context of the current literature?**

Partly

**Are all factual statements correct and adequately supported by citations?**

Partly

**Is the review written in accessible language?**

Yes

**Are the conclusions drawn appropriate in the context of the current research literature?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** I have a background in working with both static and dynamic in vitro organ models. I have worked on a static Caco-2/HT29-MTX cell based gut model to analyze the effects of engineered nanoparticles and other food additives on gut permeability, nutrient transport, and tight junction distribution in presence of a bacterial mock community. My experience with dynamic in vitro systems entails developing and optimizing a two-organ microphysiological system for secondary drug toxicity study. My work has made me well versed with the complexities involved in building a physiologically relevant microphysiological system and the significant factors that need to be considered to design it.

**We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.**

Reviewer Report 06 August 2021

<https://doi.org/10.21956/openreseurope.14783.r27228>

© 2021 Parenti R et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Rosalba Parenti**

<sup>1</sup> Department of Biomedical and Biotechnological Sciences, Section of Physiology, University of Catania, Catania, Italy

<sup>2</sup> Department of Biomedical and Biotechnological Sciences, Section of Physiology, University of Catania, Catania, Italy

**Nunzio Vicario**

<sup>1</sup> Department of Biomedical and Biotechnological Sciences, Section of Physiology, University of Catania, Catania, Italy

<sup>2</sup> Department of Biomedical and Biotechnological Sciences, Section of Physiology, University of Catania, Catania, Italy

In this manuscript entitled "*The translational roadmap of the gut models, focusing on gut-on-chip*", Malaguarnera, Graute and Corbera sought at reviewing current knowledge on experimental models of gastrointestinal diseases.

We find this review well written and pleasant to read. It is also well organized and balanced. The critical vision of the authors is offering significant insights, rising interesting scenarios such as the one pointing on increasing the reliability of gut-on-chip modelling.

The authors took into account the complex physiological environment of gastrointestinal lumen sections and advised on the reductionistic approach of gut-on-chip and organs-on-a-chip. The review is also clearly pointing out that gut-on-chip modelling is a valuable tool when studying specific physiopathological conditions, pharmaco-kinetics and host-microbes interactions.

We do not have any major points to rise, and we believe that the manuscript is ready to be shared with scientific community and with colleagues in the field. We just have some minor points:

- Figure 1 describes a roadmap of translational study of gastrointestinal models. Authors clearly described most of the concepts herein described in the text. Perhaps, it might be useful to add a further brief description of *in silico* approaches to the manuscript. In particular on the simulation of known parameters, drug docking and genetic and nutritional parameters, highlighting the limitation of such an approach.
- The part of *in vivo* modeling also deserves to be expanded a bit. Indeed, *in vivo* studies on axes between gut and other organs, such as gut-to-brain axis, is today of critical importance and of great interest for the scientific community in the field. See Tan et al. *Nature*. 2020. PMID: 32322067 and Zimmerman et al. *Nature*. 2019. PMID: 30918408.

We believe that the manuscript is overall balanced, critical and it can be considered for indexing also if authors will decide not to include the previous minor points.

## References

1. Tan HE, Sisti AC, Jin H, Vignovich M, et al.: The gut-brain axis mediates sugar preference. *Nature*. **580** (7804): 511-516 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Zimmerman CA, Huey EL, Ahn JS, Beutler LR, et al.: A gut-to-brain signal of fluid osmolarity controls thirst satiation. *Nature*. **568** (7750): 98-102 [PubMed Abstract](#) | [Publisher Full Text](#)

**Is the topic of the review discussed comprehensively in the context of the current literature?**

Yes

**Are all factual statements correct and adequately supported by citations?**

Yes

**Is the review written in accessible language?**

Yes

**Are the conclusions drawn appropriate in the context of the current research literature?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Analysis of the mechanisms underlying the processes of neurodegeneration and neuroinflammation and intercellular communication in homeostasis and disorders of the nervous system. Analysis of the mechanisms responsible for the transformation of the physiological phenotype into cancer as well as the application of advanced technologies aimed at the development of new diagnostic and therapeutic approaches to cancer.

**We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---